Overview
Synthetic cannabinoid use disorder involves problematic use of synthetic cannabinoids leading to clinically significant impairment or distress. These substances interact with the endocannabinoid system, potentially exacerbating effects through interactions with hormonal pathways 1.Diagnosis
Clinical assessment focusing on patterns of use and associated impairment.
No specific laboratory tests; diagnosis primarily based on history and behavioral observations.
Monitoring for signs of intoxication or withdrawal can aid in diagnosis 1.Management
Detoxification: Supportive care, including monitoring for severe sedation and hypothermia in cases of high-dose use 1.
Behavioral Therapy: Cognitive-behavioral therapy (CBT) and motivational interviewing are recommended adjuncts 1.
Pharmacotherapy: Limited specific drug recommendations; supportive medications for withdrawal symptoms as needed 1.Special Populations
Pregnancy: Potential interactions with progesterone receptor inhibitors like mifepristone warrant caution due to severe sedation risks 1.
Pediatrics: Limited data; cautious approach due to developing brain and hormonal impacts 1.
Elderly: Increased risk of adverse effects; careful monitoring for sedation and cognitive impairment 1.
Comorbidities: Consider interactions with hepatic metabolism; monitor for altered drug effects due to metabolic pathways 2.Key Recommendations
Monitor for severe sedation and hypothermia in synthetic cannabinoid users, especially those with concurrent use of progesterone receptor inhibitors (Evidence: Expert opinion) 1.
Implement cognitive-behavioral therapy and motivational interviewing as primary psychological interventions (Evidence: Expert opinion) 1.
Exercise caution in pregnant women due to potential severe interactions with hormonal pathways (Evidence: Expert opinion) 1.References
1 Pryce G, Giovannoni G, Baker D. Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice. Neuroscience letters 2003. link00159-9)
2 Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. Drug metabolism and disposition: the biological fate of chemicals 1992. link